GATEWAY IS NOW ACTIVELY ENROLLING AT 3 US CLINICAL SITES!

Vivet Therapeutics is a French-based biotechnology company developing gene therapies for rare liver disorders.

Wilson Disease is a rare genetic disorder that causes excess copper to build up in the body, particularly in the liver and brain. The disease is caused by mutations in a gene called ATP7B. If Wilson Disease is not diagnosed early and appropriately treated, the build-up of copper may cause serious damage to organs and results in severe disability and possibly death. This means that early diagnosis and prompt treatment is very important.

Although there are medical treatments currently available for Wilson Disease, patients need to take them for life, some patients develop side effects, and the therapeutic response is not optimal in some others with both neurological and hepatic consequences; therefore, new therapeutic options are desirable.

VTX-801 is a gene therapy treatment developed by Vivet Therapeutics that is currently under investigation in the GATEWAY study.

GATEWAY is a clinical study conducted in patients with Wilson Disease. It attempts to assess if the study drug (VTX-801) is safe, and which is the most appropriate dose that may restore durably the elimination of excess copper through the natural route.

In the GATEWAY study, all eligible patients will receive a single dose of VTX-801 in a hospital setting; no patient will receive a placebo treatment. Study participation is 5 years.

VTX-801 will not be available outside of the context of clinical trials until development has been completed, which could take a few years.

If you are interested in learning more about the study, you may find the study description and site contact details at https://clinicaltrials.gov/ct2/show/NCT04537377

You may also find additional information and responses to your questions on the dedicated website: www.gatewaytrialwilsondisease.com

In addition, please feel free to contact one of the 3 sites open for recruitment in the United States:

- **Yale University School of Medicine in New Haven**

- **University of Michigan Health System in Ann Harbor**
- **University of California Davis in Sacramento**

Additional sites are expected to be activated in the near future across the US and Europe.

Jean-Philippe Combal, Founder and CEO: "We believe that Wilson Disease deserves more attention to address the limitations of current therapeutic options. Through the restoration of physiological copper metabolism, VTX-801 gene therapy has the potential to address such need and to offer an attractive alternative to existing treatments."